Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med., 361, 947, 10.1056/NEJMoa0810699 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol., 13, 239, 10.1016/S1470-2045(11)70393-X Park, 2016, Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol., 17, 577, 10.1016/S1470-2045(16)30033-X Mok, 2018, Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations, J. Clin. Oncol., 36, 2244, 10.1200/JCO.2018.78.7994 Soria, 2018, Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, N. Engl. J. Med., 378, 113, 10.1056/NEJMoa1713137 Yamanaka, 2019, Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma, BMJ Case Rep., 12, 10.1136/bcr-2018-227383 Schuler, 2019, First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials, Lung Cancer, 133, 10, 10.1016/j.lungcan.2019.04.006 Zhang, 2018, 140PD Complex epidermal growth factor receptor (EGFR) mutations and responses to tyrosine kinase inhibitors (TKIs) in advanced lung adenocarcinomas, J. Thoracic Oncol., 13, S82, 10.1016/S1556-0864(18)30414-3 Wei, 2019, Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study, J. Cancer, 10, 4151, 10.7150/jca.30507 Gray, 2019, Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer, Clin. Cancer Res., 25, 6644, 10.1158/1078-0432.CCR-19-1126 Ahn, 2017, OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays, J. Thoracic Oncol., 12, S1771, 10.1016/j.jtho.2017.09.382 Singhi, 2019, e187 Li, 2014, Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients, Transl. Oncol., 7, 341, 10.1016/j.tranon.2014.04.006 Douillard, 2014, Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status, J. Thorac. Oncol., 9, 1345, 10.1097/JTO.0000000000000263 Tseng, 2015, Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma, J. Thorac. Oncol., 10, 603, 10.1097/JTO.0000000000000443 Karachaliou, 2015, Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial, JAMA Oncol., 1, 149, 10.1001/jamaoncol.2014.257 Yanagita, 2016, A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial, Clin. Cancer Res., 22, 6010, 10.1158/1078-0432.CCR-16-0909 Yang, 2016, Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer, Oncotarget, 7, 20810, 10.18632/oncotarget.8021 Kim, 2017, Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis, Oncotarget, 8, 65111, 10.18632/oncotarget.17786 Wu, 2017, EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6, Br. J. Cancer, 116, 175, 10.1038/bjc.2016.420 Lee, 2018, Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer, Thorac Cancer, 9, 1104, 10.1111/1759-7714.12793 Wu, 2019, Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study, Lung Cancer, 130, 18, 10.1016/j.lungcan.2019.01.016 Fukuhara, 2020, Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study, EBioMedicine, 57, 10.1016/j.ebiom.2020.102861 Mok, 2015, Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy, Clin. Cancer Res., 21, 3196, 10.1158/1078-0432.CCR-14-2594 Lee, 2016, Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02), Oncotarget, 7, 6984, 10.18632/oncotarget.6874 Taus, 2018, Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma, Clin. Lung Cancer, 19, 387, 10.1016/j.cllc.2018.03.015 Ramalingam, 2018, Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer, J. Clin. Oncol., 36, 841, 10.1200/JCO.2017.74.7576 Wang, 2018, Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial, Lancet Respir Med, 6, 681, 10.1016/S2213-2600(18)30264-9 Phallen, 2019, Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer, Cancer Res., 79, 1204, 10.1158/0008-5472.CAN-18-1082 Yu, 2020, Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial, JAMA Oncol., 6, 1048, 10.1001/jamaoncol.2020.1260 Xing, 2020, Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study, Clin. Cancer Res., 26, 6168, 10.1158/1078-0432.CCR-20-2081 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Kim, 2018, A Comparative Study for Detection of EGFR Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories, Biomed. Res. Int., 2018 Richardson, 2020, The role of asymptomatic screening in the detection of recurrent ovarian cancer, Gynecol Oncol Rep, 33 Walsh, 1995, Is follow-up of lung cancer patients after resection medically indicated and cost-effective?, Ann. Thorac. Surg., 60, 1563, 10.1016/0003-4975(95)00893-4 Snyder, 2018, Alliance for Clinical Trials in Oncology Network Cancer Surveillance Optimization Working, Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer, JAMA, 319, 2104, 10.1001/jama.2018.5816 Venugopalan, 2016, EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models, Oncotarget, 7, 54137, 10.18632/oncotarget.11021 Costa, 2007, BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations, PLoS Med., 4, 1669, 10.1371/journal.pmed.0040315 Kleiman, 2011, Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding, Mol. Cell, 43, 723, 10.1016/j.molcel.2011.07.014 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol., 13, 239, 10.1016/S1470-2045(11)70393-X Janjigian, 2014, Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations, Cancer Discov., 4, 1036, 10.1158/2159-8290.CD-14-0326 Kris, 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial, JAMA, 290, 2149, 10.1001/jama.290.16.2149 Chen, 2012, A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response, Nature, 483, 613, 10.1038/nature10937 de Jong, 2014, Imaging preclinical tumour models: improving translational power, Nat. Rev. Cancer, 14, 481, 10.1038/nrc3751 Chang, 2015, Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study, Biomed J, 38, 221, 10.4103/2319-4170.138320